Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Regulatory News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

Share Price is delayed by 15 minutes
Get Live Data
22.50    0.10 (0.44%)
Bid:
22.00
Ask:
23.00
Spread: 1.00 (4.545%)
Market Cap: £234.54m
SCLP Live PriceLast checked at - London Stock Exchange

Intraday Scancell Holdings Share Chart

Holding(s) in Company

19 May 2017 14:47

RNS Number : 7114F
Scancell Holdings Plc
19 May 2017
 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Scancell Holdings plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

Calculus Capital Limited

4. Full name of shareholder(s)  (if different from 3.):iv

Reyker Nominees/Investec Wealth and Investment

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

11 May 2017

6. Date on which issuer notified:

19 May 2017

7. Threshold(s) that is/are crossed orreached: vi, vii

18%,17%,16%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Ordinary Shares

ISIN: GB00B63D3314

49,203,353

49,203,353

50,203,353

50,203,353

15.3%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

50,203,353

15.3%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

N/A

Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will cease to hold:

N/A

12. Date on which proxy holder will cease to hold voting rights:

N/A

13. Additional information:

N/A

14. Contact name:

Calculus Capital Limited

15. Contact telephone number:

0207 493 4940

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLLLFSVEEIALID
Date   Source Headline
28th Apr 20267:00 amRNSFDA Fast Track Designation for iSCIB1+
2nd Apr 20267:00 amRNSScancell announces CFO transition
29th Jan 20267:00 amRNSHalf-year Financial Report
26th Jan 20267:00 amRNSFDA clearance of IND application for iSCIB1+
22nd Jan 20267:00 amRNSNotice of Results
9th Dec 20257:00 amRNSContinued improvement in PFS with iSCIB1+
7th Nov 20257:00 amRNSResearch Update
30th Oct 20253:30 pmRNSResult of AGM
3rd Oct 20257:00 amRNSNotice of AGM
16th Sep 20257:00 amRNSDirector Dealing
11th Sep 20257:00 amRNSFinal Results
4th Sep 20257:00 amRNSNotice of Results
8th Aug 202512:31 pmRNSDirector Dealing
4th Aug 202510:23 amRNSDirector/PDMR Shareholding
22nd Jul 20257:00 amRNSStrong Phase 2 data on iSCIB1+ in Melanoma
16th Jul 20257:00 amRNSShare Option Exercise
25th Jun 20257:00 amRNSScancell initiates new arm in SCOPE Phase 2 study
21st May 20257:00 amRNSDirector Dealing
14th Apr 20257:00 amRNSPartnership with NHS Cancer Vaccine Launch Pad
1st Apr 20257:00 amRNSScancell to present at 2025 AACR Annual Meeting
20th Feb 20257:00 amRNSIssue of share options
17th Feb 20257:00 amRNSScancell presenting at AACR IO conference
30th Jan 20257:00 amRNSInterim Results
23rd Jan 20257:00 amRNSNotice of Interim Results
9th Jan 20257:00 amRNSModi-1 Vaccine Achieves Early Clinical Validation
9th Dec 202411:41 amRNSResult of Retail Offer and Total Voting Rights
5th Dec 202412:39 pmRNSResult of Placing and Subscription
4th Dec 20246:03 pmRNSRetail Offer for up to £1 million
4th Dec 20245:59 pmRNSProposed fundraise in excess of £8.5 million
4th Dec 20247:00 amRNSSecond Commercial License Agreement with Genmab
18th Nov 20247:00 amRNSPositive data from Phase 2 SCOPE trial with SCIB1
25th Oct 20243:26 pmRNSResult of Annual General Meeting
24th Oct 20247:00 amRNSHolding(s) in Company
22nd Oct 20247:00 amRNSScancell Appoints Dr Phil L’Huillier as CEO
1st Oct 20247:00 amRNSNotice of AGM
24th Sep 20247:00 amRNSResults Year Ended 30 April 2024
18th Sep 20247:00 amRNSNotice of Final Results
17th Sep 20247:00 amRNSStrategic Partnership with PharmaJet
2nd Sep 20247:00 amRNSScancell to attend upcoming conferences
30th Jul 20247:17 amRNSScancell Appoints Dr Nermeen Varawalla as CMO
30th Jul 20247:00 amRNSScancell Appoints Dr Nermeen Varawalla as CMO
24th Jul 20247:00 amRNSUpdate from iSCIB1+ Clinical Advisory Meeting
10th Jul 20247:00 amRNSAppointment of Dr Florian Reinaud to the Board
2nd Jul 20247:00 amRNSExtension of Convertible Loan Notes
1st Jul 20247:00 amRNSBlock Listing Return and Total Voting Rights
21st Jun 20247:00 amRNSChange of Nominated Advisor
12th Jun 20247:32 amRNSAgreement with major biotech
31st May 20247:00 amRNSScancell to attend upcoming conferences
30th May 20247:00 amRNSUpdate on ModiFY trial
24th May 20247:00 amRNSScancell to present at ASCO Annual Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.